Epilepsy Research
XPF-010-301 (X-T0LE2): A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal Onset Seizures
Sponsor: Xenon Pharmaceuticals, Inc.
Phase of Development: Phase III
Study Duration: Up to 6.5 months
Enrollment Status: Open
Principal Investigator: Rajiv Aggarwal, M.D.
XPF-010-304 (X-TOLE4): A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Adults Diagnosed With Epilepsy
Sponsor: Xenon Pharmaceuticals, Inc.
Phase of Development: Phase III
Study Duration: Approximately 1 year
Enrollment Status: Open
Principal Investigator: Rajiv Aggarwal, M.D.
Research Contacts: Dr. Aggarwal or Madison Irwin, Clinical Research Coordinator, at 763-302-4162 or Madison.Irwin@mpls-clinic.com, or David Harvey, MN, RN, Clinical Research Nurse, at 763-302-4359 or David.Harvey@mpls-clinic.com.
